Just five weeks ago, shares in Sareum Holdings rocketed over 150% after it announced its cancer drug candidate had been licensed to Nasdaq listed ProNAi Therapeutics. The company discovers and develops innovative drug candidates aimed at cancers and autoimmune diseases and its results are out. Dr Tim Mitchell is the CEO and he joined Share Radio to discuss the numbers.
